AMH and polycystic ovary syndrome: In 2022, Magagnini et al. evaluated the effect of VLCKD on markers (SHBG, AMH, progesterone) suggested to be predictive of metabolic and ovulatory dysfunction in patients with PCOS and obesity (n = 25) for 12 weeks.